2. Academic Validation
  3. Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways

Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways

  • Biomed Pharmacother. 2021 Sep:141:111874. doi: 10.1016/j.biopha.2021.111874.
Weixin Zhao 1,  Yixiao Yan 1,  Zhongxiang Xiao 2,  Meihong Wang 1,  Mingjiang Xu 1,  Zhe Wang 3,  Yi Wang 1,  Zaishou Zhuang 4,  Daona Yang 4,  Gaozhi Chen 5,  Guang Liang 6
Affiliations

Affiliations

  • 1 Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
  • 2 Department of Pharmacy, the Affiliated Yueqing Hospital, Wenzhou Medical University, Yueqing, Zhejiang 325699, China.
  • 3 Department of Pharmacy, the Affiliated Second Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
  • 4 Affiliated Cangnan Hospital, Wenzhou Medical University, Cangnan, Zhejiang 325800, China.
  • 5 Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China. Electronic address: cgztc@163.com.
  • 6 Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, Zhejiang 311399, China; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China. Electronic address: wzmcliangguang@163.com.
PMID: 34229251 DOI: 10.1016/j.biopha.2021.111874
Abstract

Bicyclol has been approved as an anti-inflammatory, hepatoprotective drug in China to treat various forms of hepatitis. However, the role of bicyclol in non-alcoholic fatty liver disease (NAFLD) is unknown. In this study, NAFLD model was established by feeding mice with high fat diet (HFD) for 16 weeks, and bicyclol (25 and 50 mg/kg) were orally administered for the last 4 weeks. Although bicyclol treatment did not change the body weight of mice, bicyclol administration significantly improved HFD-induced dyslipidemia, NAFLD activity score, hepatic Apoptosis, systemic and hepatic inflammation, and liver fibrosis in the mice. Moreover, bicyclol treatment significantly inhibited HFD-induced activation of MAPKs and NF-κB signaling pathways that may mediate the inflammatory responses. Further in vitro studies showed that bicyclol pretreatment markedly ameliorated PA-induced inflammatory responses in human hepatocyte HL-7702 cells and mouse peritoneal macrophages through inhibiting MAPKs and NF-κB signaling pathways. These data indicated that bicyclol may have the potency to treat NAFLD by reducing inflammation.

Keywords

Bicyclol; Inflammation; MAPKs; NAFLD; NF-κB.

Figures
Products